Want a Ride with $ACET?There's an interesting fundamental catalyst behind this – it will re-test $1.20 and trade higher!
PD: We duplicated 3 client accounts since Monday.
0HX7 trade ideas
$ACET Adicet Bio Inc Long term PT 21 and higherAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
ACET Trending UpPublishing this on the Daily scale as well.
Price needs to find support at the .50 and then the .618 fib levels to move up to the target at 1.618 extension .
Appears to be currently in a falling wedge with a $12.50 bottom which is also the .618 level of the recent price action.
Will be a challenge with the current market conditions but technical indicators show promise.
ACET Trending UpPrice needs to find support at the .50 and then the .618 fib levels to move up to the target at 1.618 extension.
Appears to be currently in a falling wedge with a $12.50 bottom which is also the .618 level of the recent price action.
Will be a challenge with the current market conditions but technical indicators show promise.
Adicet Bio. Down. ACETFirst biopharma that is about to flip in our most recent experience. Just look, this baby can't climb forever.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
Leg C becomes Leg BHello, it has been a while since I write. With this stock, I wrote Leg B twice. If you read my previous article, you know that there is a Leg B and Leg C, but in this article, I wrote Leg B twice why because Leg C becomes another Leg B unless there is a change in trend.
Thank you for reading! Again, my writing is just an opinion, an idea, and not a recommendation.
Greenfield tql
$ACET entry PT 12.70-13 Long term Target PT 32 and higherGuggenheim Maintains Buy on Adicet Bio, Raises Price Target to $32
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.
ACET - Long Setup Break above 8.53, Stop signal 7.66. First target 11.37. Insider selling from CEO at 10.53-15.34 throughout the year.
Long play in ACET, entry: 10.55, target: $15.00, stop 9.70On Friday June 18, ACET was once again traded down to the support at $10. It came back strong, however, and closed near the high of the day. There was heavy volume as buyers obviously saw value at this level.
If it continues up this week, preferably under volume, I would be long with targets at the $12 and $15 levels (previous resistance). A good stop level would be the 52-week low at 9.71. At target 1, the risk reward ratio isn’t great at 1.7, but it is target 2 that is the main target and have a ratio of 5.2.
A stop of -8.5% can seem high but with a potential profit of 42% I think it is defendable. An alternative stop could be just below the low of June 18 (10.05).
Entry: 10.55
Target 1: 12.00 (13.7%)
Target 2: 15.00 (42.2%)
Stop: 9.70 (-8.5%)
Not seeing this as a long-term play even though analysts seem to like it. The average price target according to Yahoo Finance is $28.29. If that level is in the cards, then getting in at $10 would be a good deal. However, there have been lots of insider selling and no buying. As late as June 15, founder and board member Jakobovits Aya, sold another 3,847 shares.
This is a trade idea and not a recommendation. You are responsible for your own trades. Never trade with money you cannot afford to lose.
ACET keep eye on 12USD levelNASDAQ: ACET price target $27.50 (very bullish/strong buy), it has been coming down from July 20USD touched 10USD and consolidating. Will it reach pre-covid level (48-64USD) ...it has long way to go. But if it reaches avoce 21USD it may get there. I will buy when it touches 12USD again. Or goes above 16USD.
ACETRisque de rebondir sur sa résistance et retourner vers le bas. Si perce ça résistance, peut-être bon.
ACET might go into Gap fill short term Target approx 3.0if Volume momentum keeps going i think we see 3.0 test
break of 3 could lead into huge gap fill
ACET DROPPING HARDLY, MORE DOWNSIDE EXPECTEDACET is dropping form 26$ to 20$ but i think it is only the beginning. After the pullback i'm expecting one more wave down. Possible target on chart.
